Good MorningEquity markets pulled back from their new highs on Thursday after a double-shot of news gave the market a dose of reality. The October read of CPI came in above expectations, belying the need for aggressive FOMC rate cuts, while jobless claims data came in at the highest level in two years. The jobless claims raise fear of a recession even while inflation remains hot. At 258,000 weekly new claims, the unemployment data shows a sharp increase in newly jobless Americans but is offset by a decline in total joblessness. The takeaway is that the data remains spotty, and the US economy is on track for a soft landing.
Next week will be challenging for equity markets. Earnings season will continue its ramp to high gear with reports from big pharma and the first of the FAANG names. Netflix is expected to report on Thursday after the market close and has a high bar to beat. More than 90% of the analysts covering Netflix have raised their estimates for the quarter, forecasting a 15% YoY gain in revenue, and whisper numbers are much higher. The question is not whether Netflix can produce value but whether competition and consumer weakness will sap strength and impact the longer-term growth outlook.
Featured: 25 candidates screened. 5 made it. (Ad) 
|
Industrials | |
Airline and transportation stocks have been under pressure from weakening consumer discretionary trends lately, especially as inflation is now threatening to spike again after the – arguably premature – interest rate cuts coming from the Federal Reserve (the Fed), being the most aggres... Read the Full Story |
|
From Our Partners | | Tobacco, telecom, pipelines, and healthcare real estate trade at 10 to 15 times earnings while the index yields about 1 percent.
A free report highlights seven cash-generating stocks with a 5 percent forward yield floor and roughly 6.5 percent average cash yield, capped at two picks per sector.
Each pick includes coverage numbers and an honest bear case. Five of the seven have raised payouts for 17 to 56 straight years. | | Get the seven high-yield dividend stocks free now |
|
Consumer Discretionary | |
While the world of e-commerce in the United States and Europe is dominated by Amazon.com Inc. (NASDAQ: AMZN) and arguably shared with Chinese giant Alibaba Group (NYSE: BABA), a new Latin American territory has been taken over by the region’s leading platform instead, with a particular inter... Read the Full Story |
|
Consumer Discretionary | |
Domino’s Pizza (NYSE: DPZ) continues to face challenges but is navigating the conditions well. The Q3 results show that the Hungry for MORE strategy continues to pay off, setting the business up for accelerating growth and leveraging bottom-line results when macroeconomic conditions improv... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Healthcare | |
Small-cap stocks faced a challenging environment for the last several years as inflation and high interest rates dampened lending opportunities. These companies—which are often in the early stages of development and lack stability—rely heavily on debt to fuel their growth.
Fortunately... Read the Full Story |
|
Consumer Discretionary | |
Analysts' sentiment is important in determining the right time to buy stock. However, the trend in sentiment and coverage is more important than the consensus rating. A Moderate Buy or Buy rating doesn’t mean as much if recent revisions include downgrades, price target revisions, and lapsed ... Read the Full Story |
|
From Our Partners | | One fund holds Nvidia, CrowdStrike, Palantir and other major AI names, and pays a 34% annualized distribution rate.
Instead of guessing which AI stock wins, this fund delivers income every single Thursday, up to $1,051 a month.
Chief Income Strategist Tim Plaehn breaks down what's inside the fund and how the weekly payouts work. | | Watch the free video to see how the weekly payouts work |
|
Healthcare | |
The stock market’s impressive and resilient performance in 2024, with the SPDR S&P 500 ETF (NYSE: SPY) up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upsid... Read the Full Story |
|
Consumer Discretionary | |
On a day when the benchmark S&P 500 index hit a record high, Carnival Corporation's (NYSE: CCL) popping 7% to its highest level in more than 2 years says a lot. As one of the hardest hit industries during the COVID pandemic, cruise lines have been closely watched in recent years to see if they... Read the Full Story |
|
Technology | |
There’s a saying that stocks don’t move in one direction all the time. Palantir Technologies Inc. (NYSE: PLTR) is testing the logic behind that saying. PLTR stock is up a whopping 151% in 2024 nearly matching the 168% gain in NVIDIA Corp. (NASDAQ: NVDA).
Furthermore, the stock is up ... Read the Full Story |
|
Markets | |
Now that the stock market is going into a new trend and cycle, sparked by the recent Federal Reserve (the Fed) interest rate cuts initiating a potential money shift over the next few quarters, investors might start to prefer safer spaces and stocks to put their capital into. Among all these prefer... Read the Full Story |
|
Markets | |
It might seem strange to say a stock is still irresistible after it’s rallied 350% and just closed at a new high, but it’s hard not to with Netflix, Inc (NASDAQ: NFLX). For a company that had to watch its shares lose 80% of their value just 2 years ago, it’s been a remarkable tur... Read the Full Story |
|
Friday's Early Bird Stock Of The Day GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. | Should I Buy GSK Stock? GSK Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of GSK was last updated on Thursday, October 08, 2026 at 6:53 PM.
GSK Bull Case -
GSK plc is currently trading at $46.52, which is significantly below the average 12-month analyst price target of $56.50, suggesting substantial upside potential for investors who believe the market is undervaluing the company's recent pipeline additions and strategic initiatives.
-
The company has successfully expanded its oncology pipeline through recent high-profile deals, including a $10.6 billion acquisition of Nuvalent and a licensing agreement with HUTCHMED for HMPL-A830, which aims to diversify growth beyond its existing core products and address the upcoming patent cliff in its HIV franchise.
-
GSK plc offers an attractive dividend yield of 3.81%, supported by a recent increase in its quarterly dividend to $0.4515, providing a steady income stream for investors while the company maintains a payout ratio of 55.63% that leaves room for further growth investments.
-
Recent positive clinical data for ViiV Healthcare's long-acting HIV treatment Cabenuva, which met its primary endpoint in the phase IIIb CROWN study, reinforces the strength of GSK's HIV franchise and supports the company's strategy of managing its key therapeutic areas proactively.
-
With a low beta of 0.33, GSK plc exhibits lower volatility compared to the broader market, making it a potentially stable investment option for risk-averse investors seeking exposure to the pharmaceutical sector without significant price swings.
GSK Bear Case -
The consensus rating from eleven brokerages covering GSK plc is "Hold," with two analysts issuing sell ratings, indicating that a significant portion of the financial community is cautious about the stock's near-term performance and potential risks.
-
GSK faces a significant patent cliff in its HIV franchise, which could lead to a substantial loss of revenue unless the company successfully executes its strategy of reinvesting cost savings into R&D and M&A to offset the impact of expiring patents.
-
Recent labor advocacy efforts to preserve jobs at GSK's Dresden vaccine plant in Germany highlight potential workforce and restructuring concerns, which could create execution costs or reputational pressure for the company.
-
The company's debt-to-equity ratio of 0.81 and current ratio of 0.82 suggest that GSK may face liquidity challenges or higher financial leverage, which could limit its flexibility in responding to market downturns or unexpected expenses.
-
Short interest in GSK plc has increased in recent months, with shares shorted rising to 14.65 million as of September 2026, indicating that some investors are betting against the stock's future performance and potentially signaling underlying concerns about the company's outlook.
| | View Today's Stock Pick |
|
